Coronavirus, Covid-19 Vaccine Covaxin Bugawa Ta karshe: Bharat Biotech's Covaxin

Fasali 19

Bharat Biotech's Covaxin rigakafi ne wanda ba a kunna shi ba daga COVID-19 wanda aka haɓaka a Indiya. Anan ga wasu sabbin sabuntawa akan Covaxin:

  • Tabbatacce: A cikin bayanan gwaji na asibiti na wucin gadi, an nuna Covaxin yana da ƙimar inganci na 77.8% a kan cututtukan COVID-19 masu alama. An kuma nuna cewa maganin yana da tasiri kashi 93.4 cikin ɗari a kan mummunan lamuran COVID-19.
  • Amincewa: An amince da Covaxin don amfani da gaggawa ta Hukumar Lafiya ta Duniya (WHO), kuma an amince da ita don amfani a Indiya da wasu ƙasashe da dama.
  • Adadin haɓakawa: Bharat Biotech ya ba da rahoton cewa an nuna ƙarar kashi na Covaxin yana haɓaka matakan rigakafi sosai, kuma kamfanin yana shirin gudanar da gwaji na asibiti kashi 3 don kimanta aminci da ingancin kashi na uku na rigakafin.
  • Samar iya aiki: Bharat Biotech ya haɓaka ƙarfinsa na samar da Covaxin, da nufin samar da allurai biliyan 1 na rigakafin kowace shekara. Kamfanin ya kuma sanya hannu kan yarjejeniyoyin da wasu kasashe da dama don samar da Covaxin.
  • Bambanci: Bharat Biotech ya ba da rahoton cewa Covaxin yana da tasiri a kan bambance-bambancen Delta na kwayar cutar, wanda a halin yanzu ya zama babban damuwa a duniya.

Gabaɗaya, Covaxin ya nuna sakamako mai ban sha'awa a cikin gwaji na asibiti kuma an yarda da shi don amfani da gaggawa a ƙasashe da yawa.